Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellnovo appoints Sorin and Baxter veteran as chairman

This article was originally published in Clinica

Executive Summary

UK start-up Cellnovo has appointed Eric Beard chairman. Mr Beard is currently a senior advisor to US investment firm The Carlyle Group. Between 2003 and 2008, he was president for cardiovascular device specialist Sorin Group's international operations, where he was involved with the acquisition of disposable cardiovascular device developer Gish Biomedical in 2010 (www.clinica.co.uk, 9 June 2010). Mr Beard went on to become president and CEO of Gish. Before joining Sorin, he worked for Baxter International for 28 years, where he was initially responsible for Baxter's renal products in various countries, before ultimately becoming president of Baxter EMEA, covering all of its business in Europe, the Middle East and Africa. London-based Cellnovo is developing a mobile diabetes management system, which it CE marked for sale in Europe in September.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel